We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Generic Drugmakers’ Use of Premature Patent Notices Pushes FDA to Take Action
Generic Drugmakers’ Use of Premature Patent Notices Pushes FDA to Take Action
Efforts by generic drugmakers to initiate patent litigation early by sending premature Paragraph IV certification notices to innovators are prompting the FDA to crack down on the practice, though it’s not yet clear what actions the agency intends to take.